Drug Trial Radar · NCT06966635
Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets
Last checked: Nov 20, 2026Latest source record: May 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
312
Planned (sponsor's estimate)
Start
Apr 10, 2024
Primary completion
Dec 31, 2025
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Huashan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate whether alkalization has the effect of lowering uric acid and reducing gout flare and determine whether alkalization has a role in the prevention and treatment of urinary calculi in gout, the research participants were divided into the control group, the potassium citrate group and the sodium bicarbonate group. 2 alkalization groups took potassium citrate three times a day 2.16g each time, or sodium bicarbonate three times a day, 1.0g each time, on the basis of the standard uric acid-lowering treatment plan. The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable.
Conditions
- Hyperuricemia or Gout
- Nephrolithiasis
Interventions
Sodium Bicarbonate Oral CapsuleDrug
On the basis of the standard uric acid-lowering treatment plan, sodium bicarbonate should be taken three times a day, 1.0g each time
Potassium Citrate TabletsDrug
On the basis of the standard uric acid-lowering treatment plan, potassium citrate was taken three times a day, 2.16g each time
uric-acid-lowering drugDrug
The control group was treated with the standard uric acid-lowering treatment regimen alone. Uric acid-lowering treatment plan: Maintain the individualized uric acid-lowering treatment plan at the time of patient enrollment. Traditional uric acid-lowering treatment plans include drugs that reduce uric acid production such as febuxostat and allopurinol, and drugs that increase uric acid excretion such as benzbromarone. At the time of enrollment, the uric acid-lowering drugs were stable. The treatment plan for lowering uric acid remained unchanged for 4 weeks after enrollment in the clinical study until the endpoint.
Primary outcomes
What the sponsor says the trial is designed to measure.
- serum uric acidTime frame: From enrollment to the end of treatment at 48 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan hospital, Fudan university
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.